<DOC>
	<DOC>NCT02525172</DOC>
	<brief_summary>The purpose of this study is to assess anti-recombinant human acid α-glucosidase (anti-rhGAA) antibody titers after treatment with immune modulation therapy in patients of Pompe disease.</brief_summary>
	<brief_title>Immune Modulation Therapy for Pompe Disease</brief_title>
	<detailed_description />
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Immunoglobulins, Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho(D) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>The patient (and/or patient's legal guardian if patient is &lt; 18years) must provide written informed consent prior to any studyrelated procedures that are performed; The patient must have a confirmed diagnosis of Pompe disease defined as a documented acid αglucosidase (GAA) enzyme deficiency from blood samples or 2 GAA gene mutations; The patient (and/or legal guardian) must have ability to comply with clinical protocol; Regimen A only: The patient is receiving enzyme replacement therapy, exhibits clinical decline, and has persistent high antirecombinant human acid αglucosidase (antirhGAA) antibody titers and/or tested positive for antibodies that inhibit enzymatic activity and/or uptake of Myozyme; Regimen B only: The patient is crossreactive immune material (CRIM) negative AND have not received Myozyme infusion prior to enrollment The patient is at risk of reactivation or is a carrier of Hepatitis B or Hepatitis C; The patient is at risk of reactivation of tuberculosis or has regular contact with individuals who are being actively treated for tuberculosis; The patient has used any investigational product (other than alglucosidase alfa) within 30 days prior to study enrollment; The patient is pregnant or lactating; The patient has had or is required to have any live vaccination within one month prior to enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>immune modulation therapy</keyword>
	<keyword>acid α-glucosidase</keyword>
	<keyword>antibody</keyword>
</DOC>